Conversely, truncated isoforms of SST5 (SST5TMD4), recently identified in different tumor histotypes as possible inhibitors of canonical SRIF activity on its receptors [73], were reported to stimulate the pro-angiogenic pathways. Here, SSTR5 is linked to neoplasm.